A 9-year-old girl with suspected lupus nephritis was referred with a high-grade fever lasting for 9 days, a small-spotted rash on the lower limbs, and left ankle and right wrist swelling. The patient also reported not “feeling well” for a period of approximately 1 month before the onset of these symptoms, without any other specific complaints. The following laboratory abnormalities were noted before referral: leukopenia and anemia, increased erythrocyte sedimentation rate (ESR) and elevated C-reactive protein (CRP) level, increased d-dimer concentration, positive anti-dsDNA antibodies, erythrocyturia and proteinuria (1.0 g/l). The concentrations of serum creatinine, urea, and uric acid were in normal range. Before the definitive diagnosis could be established, she had received ceftriaxone and antihistamines.
The physical examination on admission to the nephrology ward revealed a butterfly-shaped erythematous rash on the face, a well-delineated maculopapular rash on the lower limbs and buttocks, along with cervical, submandibular and inguinal lymphadenopathy. In the laboratory work-up, serum urea and creatinine concentrations were increased, with an estimated GFR of 66 ml/min/1.73 m2 according to the revised Schwartz formula. Mild proteinuria and hematuria were found in urinalysis. The complete blood count and blood smear were unremarkable apart from a mild anemia with a positive direct Coombs test, suggestive of possibly immune-mediated hemolysis. Concordantly with the suspicion of lupus nephritis, the concentrations of C3 and C4 complement components were significantly decreased (0.24 g/l and 0.05 g/l respectively). The inflammatory markers (CRP and procalcitonin) were within the normal range. Other noticeable laboratory findings were increased d-dimer and triglycerides (TG) concentrations, as well as elevated activity of aspartate aminotransferase (AST). Ferritin concentration was slightly below, whereas fibrinogen concentration was slightly above the respective reference values (Table 1). ANCA profile, anticardiolipin antibodies and anti-glomerular basement membrane (anti-GBM) antibodies were negative. Virologic tests for HBV, HCV, and EBV as well as blood and urine cultures were also negative. Increased renal echogenicity, splenomegaly, and a moderate pericardial effusion were found in ultrasound.
Table 1
The patient’s laboratory measurements
Parameter | At admission | 4 days after admission | 3 weeks after admission | 4 weeks after admission (1 day after kidney biopsy) | 5 weeks after admission | Normal range |
|---|---|---|---|---|---|---|
Hemoglobin (mg/dl) | 10.1 | 9.1 | 12.2 | 9.5 | 11.6 | 12–15 |
White blood cell count (× 103/μl) | 4.2 | 1.4 | 10.9 | 9.7 | 7.5 | 4–10.5 |
Neutrophils (× 103/μl) | 1.7 | 0.77 | 6.27 | 9.5 | 1.46 | 1.6–6 |
Platelet count (× 103/μl) | 218 | 193 | 461 | 260 | 622 | 150–450 |
Fibrinogen (mg/dl) | 414 | 256 | 327 | 551 | - | 200–400 |
d-dimer (μg/ml) | 2.5 | > 20 | 0.32 | 3 | 0.48 | 0–0.5 |
Ferritin (μg/l) | 14.9 | 540 | 39.7 | 596 | 72 | 20–200 |
AST (IU/l) | 49.2 | - | 17.1 | - | 14.6 | 0–40 |
LDH (IU/l) | - | 711 | 143 | 301 | - | 120–300 |
Creatinine (μmol/l) | 82 | 52 | 46 | 62 | 43 | 34–65 |
Triglycerides (mmol/l) | 4.11 | 4.6 | 2.2 | 3.5 | 4.3 | < 1.7 |
CRP (mg/l) | 2.41 | 40 | 0.5 | 50 | 1.15 | 0–5 |
PCT (ng/ml) | 0.37 | 0.6 | - | 17 | 0.6 | 0.02–0.5 |
Proteinuria (g/l) | Trace | 1.38 | Negative | Negative | Negative | Negative |
eGFR (ml/min/1.73 m2) | 66 | 104 | 118 | 87 | 126 | > 90 |
Anzeige
After admission, the patient’s state deteriorated over a period of a few days, with an unremitting high-grade fever, significant weakness and drowsiness, the spreading of the rash over the trunk, upper limbs and whole face, progressing ultimately into a generalized erythema, and further decrease of the kidney function to eGFR nadir of 56 ml/min/1.73 m2.
A treatment with pulsed methylprednisolone (10 mg/kg) was initiated at this point, despite the lack of a kidney biopsy result, because of the severity of the disease and the strongly suggestive clinical picture as well as auto-antibodies profile, with highly positive antibodies against native SS-A (60 kDa) (+++), recombinant Ro-52 (++), dsDNA (+++), nucleosomes (++), and histones (++).
After the first pulse, the general state of the patient improved slightly, although the skin symptoms were still strongly pronounced, and laboratory tests showed an alarming evolution, with the exacerbation of anemia, leukopenia, neutropenia, increase of CRP concentration, extremely high d-dimer concentration, increase in activity of lactate dehydrogenase, and persistent proteinuria (in morning urine spot). The concentration of TG rose, whereas ferritin concentration increased more than 35-fold, reaching the level of 540 μg/l.
Intravenous cyclophosphamide pulse therapy according to the Euro-Lupus regimen [1] was added to the ongoing steroid treatment and resulted in a radical improvement of the patient’s condition. The fever and skin changes subsided; laboratory test results, including renal function parameters and ferritin concentration, normalized. After 4 weeks, when clinical status was stabilized, a kidney biopsy was performed in order to assess the type and intensity of renal involvement. After the procedure a recurrence of high-grade fever was observed with a raise CRP concentration up to 50 mg/l, PCT 17 ng/ml, d-dimer 3 μg/ml, ferritin level 596 μg/l, and TG 3.5 mmol/l. This early relapse necessitated an intensification of the immunosuppressive treatment (high doses of intravenous steroids) with, again, a quick significant improvement. The kidney biopsy revealed diffuse proliferative lupus nephritis, consistent with class IV G (A/C) according to the ISN/RPS classification, and IV-C according to the WHO classification.
Anzeige
Questions:
1.
What is the complication that occurred in this case of lupus nephritis?
2.
Are further diagnostic procedures necessary to confirm the diagnosis?
3.
What is the optimal treatment of the observed abnormalities?
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.